New Jersey's medicaid waiver for acquired immunodeficiency syndrome

C. Merzel, S. Crystal, U. Sambamoorthi, D. Karus, C. Kurland

Research output: Contribution to journalArticlepeer-review


This article contains data from a study of New Jersey's home and community-based Medicaid waiver program for persons with symptomatic human immunodeficiency virus illness. Major findings include lower hospital costs and utilization for waiver participants compared with general Medicaid acquired immunodeficiency syndrome admissions in New Jersey. Average program expenditures were $2,400 per person per month. Based on study findings, it is evident that the waiver program is an important means of providing financial benefits and access to services and that comprehensive case management is a critical factor in assuring program quality.

Original languageEnglish (US)
Pages (from-to)27-44
Number of pages18
JournalHealth Care Financing Review
Issue number3
StatePublished - 1992

ASJC Scopus subject areas

  • Health Policy


Dive into the research topics of 'New Jersey's medicaid waiver for acquired immunodeficiency syndrome'. Together they form a unique fingerprint.

Cite this